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ABSTRACT 
TAMOXIFEN - 5-FLUOROURACIL SYNERGY IN HUMAN 
BREAST CANCER CELL LINES: CORRELATING IN VITRO 
SYNERGY WITH THE CURRENT MODEL ESTROGEN RECEPTOR 
Brent Roderick Wilfred Moelleken 
1985 
The potential mechanisms of in vitro synergy between 
the antiestrogen tamoxifen (TAM) and the pyrimidine analog 
5-fluorouracil (5FU) in cultured breast cancer cells (MCF-7, 
T47-D) are explored from three aspects: the influence of 
TAM on 5-FU metabolite incorporation into RNA, the influence 
of 5-FU on the binding of (3H) estradiol to the estrogen 
receptor (ER) , and the effects of 5-FU on ER binding to 
DNA-cellulose, an in vitro correlate of nuclear chromatin. 
While overall incorporation of 5-FU into RNA was decreased, 
TAM increased incorporation of metabolites of 5-FU into the 
32-45S species RNA as determined by sucrose gradient 
centrifugation. At low, minimally toxic doses of 5-FU, (3H) 
estradiol binding to ER is increased. Since higher, more 
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cytotoxic doses of 5-FU actually decrease (3H)E2 binding to 
ER, this is an unlikely primary mechanism of synergy between 
TAM and 5-FU, in these cells. In other preliminary studies 
it appears that toxic doses of 5-FU increase binding of (3H) 
estradiol-ER to DNA-cellulose. From these results a 
mechanism can be postulated: 5-FU incorporation into RNA 
impairs processing of ribosomal and messenger RNA, 
inhibiting a negative feedback loop that specific low 
molecular weight RNA sequences exert on estrogen receptors. 
This, in turn, potentiates tamoxifen's growth-inhibiting 
effects on nuclear chromatin. 
Alternate theories of TAM-5-FU synergy are also 
considered. The literature is reviewed with respect to 
applicable general aspects of breast cancer, MCF-7 cell 
culture and in vitro techniques for measuring ER activity 
and function, Scatchard analysis, the role of steroid 
receptors in human malignancy, known mechanisms of action of 
TAM and 5-FU, and lastly, the relationship of this 
information to the current model of estrogen receptor 
function is discussed. 

CHAPTER I 
BREAST CANCER IN GENERAL 
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Breast cancer continues to be a serious and widespread 
health problem for women in the United States. Death rates 
for breast cancer are tied at 18% with lung cancer for the 
highest percentage of deaths in women caused by cancer, 
followed by cancer of the colon and rectum at 15%. 
Still, breast cancer has the highest cancer incidence 
in women, comprising 26% of all newly diagnosed cases of 
cancer. It is estimated that there were 115,000 newly 
diagnosed cases of invasive breast cancer in women in 1984 
(144) . 
In spite of the many advances in chemo- and endocrine 
therapy, early detection and surgery, examination of the 
age-adjusted cancer death rates for females from 1930-1979 
shows an unchanging rate for deaths from breast cancer at 
27/100,000 females. Fortunately this does hot mean that 
modern therapy has had no effect on the rate, which has 
risen slowly from a 5-year survival rate in 1960-63 of 63% 
for white and 46% for black women; in 1970-73, 68% for white 
women and 51% for black women; and in 1973-80, the most 
recent figures available, to 74% and 62% for white and black 
women, respectively. Two trends are noticeable — increased 
survival at 5 years and decreased disparity between survival 
of white and black women with breast cancer. 
On the surgical front, there is a recent trend away 
from radical operations when the primary tumors are small. A 
clinical trial of 701 women with breast cancers measuring 
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less than 2cm without palpable axillary nodes, in which 
women were randomized to one of two therapies - either 
radical mastectomy or a combination of quadrantectomy, 
axillary dissection and radiotherapy. Both groups received 
chemotherapy with the CMF regimen (cyclophosphamide, 
methotrexate, and fluorouracil). There were fewer 
recurrences in the quadrantectomy group; statistically, 
however, there was no difference, indicating that in women 
with tumors of less than 2cm, without palpable axillary 
nodes, mastectomy appeared to involve unnecessary mutilation 
(153). 
Still, only about one half of all breast cancers are 
definitively cured; most of the curable patients have tumors 
confined to the breast and do not have extension of their 
disease to the axillary nodes. 
From this information, the concept of breast cancer as 
a systemic disease has emerged; if the axillary nodes are 
positive, this can be operationally seen as a manifestation 
of a systemic disease warranting systemic treatment — only 
in this fashion can microscopic metastases, not yet 
clinically evident, be cured. 
If the present incidence rates at each age remain 
constant throughout the lifetimes of women now alive — a 
reasonable expectation — breast cancer may affect one of 
every eleven women in the United States (140) . It is quite 
possible that the most decisive advances may be made against 
this disease on the cellular and ultra-structural levels. 
• 
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This thesis will attempt to shed light upon one aspect 
of breast cancer therapy that shows considerable promise — 
the combination of endocrine therapy with chemotherapy, to 
produce synergistic cytotoxicity against breast cancer 
cells, while sparing normal host tissues from added 
toxicity. This therapeutic innovation is being tested both 
in tissue culture and in preliminary clinical trials. 
More specifically, in this thesis the mechanisms 
underlying TAM-5-FU synergy are explored. In spite of its 
laboratory and clinical promise, hormonal and cytotoxic 
therapy in general remains empirical and its mechanisms 
inadequately understood. To appreciate the therapeutic 
potential of chemo-endocrine therapy, a solid foundation in 
biochemical and receptor phenomena is necessary, as well as 
an exact knowledge of the independent mechanisms of action 
of the drugs under consideration. In addition, the 
literature is reviewed with the intention of providing the 
most up-to-date view of relevant background topics. In the 
near future it is quite conceivable that one will be able to 
design rationally formulated regimens of chemo- and 
endocrine therapy for each patient, tailored to the 
individual receptor, hormonal and tissue type, as well as to 
the patient's expectations of treatment. 
EPIDEMIOLOGIC CONSIDERATIONS 
The epidemiology of breast cancer holds considerable 
■ 
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information about the pathogenesis of breast cancer. 
It is known that the frequency of breast cancer rises 
with increasing age in American women. Curiously, the 
reverse is true in Japanese women, but not in women of 
Japanese ancestry who have lived in the United States for 
two generations (143). The high dietary content of 
saturated fats in the American diet is sometimes implicated 
(supported by experimental evidence) (143); obesity has also 
been suggested (143). Interestingly, certain estrogens have 
been implicated which derive in large parts from peripheral 
conversion in adipose tissue — as well as from the female 
sex organs. 
Also, it is known that women who have menstrual 
patterns leading to lengthy, unopposed stimulation by 
estrogens (i.e. nulliparity, late age of first pregnancy, 
late menopause) have an increased risk. Other risk factors 
less readily subsumed under this theory are hypothyroidism 
and irregular menstrual cycles in many patients. 
Certainly, genetic factors play a very important role 
in breast cancer: having a sister or mother with breast 
cancer — particularly if it occurred premenopausally — 
greatly increase a woman's chance of contracting it herself. 
In the absence of atypia on histologic examination, though, 
family history is not an important predictor (52). 
The higher incidence of breast cancer in women with 
fibrocystic disease or previous breast cancer themselves is 
a well-described, but perhaps outdated concept (143) , since 
' 
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fibrocystic disease of the breast lacks specificity in 
predicting the development of breast cancer. 

CHAPTER II 
BREAST CANCER CELLS IN CULTURE 
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Most of the original work in this thesis, and a large 
portion of the background data, was obtained using human 
breast cancer cell lines, either from the MCF-7 or T-47-D 
cell lines. 
Establishing a cell line is a matter of considerable 
difficulty: investigators tried for over 20 years to 
establish a human breast cancer cell line until they finally 
succeeded in 1958 by producing the BT-20 human breast cancer 
cell line (97). 
The viability of malignant cells provided from freshly 
resected tumor samples or metastases is usually low. If the 
sample is obtained from a solid specimen, it may contain 
more supporting cells (especially fibroblasts) which tend to 
overgrow tumor cells in culture . Customarily, a lengthy 
"lag period" is noted after cells from a solid tumor have 
been implanted before a homogeneous culture grows. This lag 
period suggests that competition is occurring between the 
cells, and that the population arising ultimately is that 
most suited for the competetive environment of the culture 
flask. It is by no means necessarily the same cell type 
which predominated in the original tumor type; in fact, it 
may not even be representative of the original cells 
contained in the tumor. This seems to be a serious 
potential limitation of tissue culture experimentation 
(136). Once established, a cell line must be maintained on 
the proper culture medium and be demonstrated to be free of 
C 
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bacterial and mycoplasma contamination. Several successful 
human breast cancer cell lines, among them the MCF-7 and 
T-47-D lines, are from pleural effusions; there is little 
contamination of malignant effusions by fibroblasts (57) . 
From early studies, the concept of breast cancer as a 
population of cells with variable sensitivities to hormones 
emerges. Nenci's group in Italy demonstrated that many 
tumors contain a subset of cells that do not translocate 
bound hormone into the nucleus, although the hormones were 
taken up normally into the cytoplasm (119) . This is a 
phenomenon which has important implications in assessing 
receptor status. Of 150 breast tumors examined, fewer than 
10% of them were uniformly either receptor positive or 
receptor negative. This realization has direct clinical 
relevance and may explain the quick emergence of drug or 
endocrine resistant cell strains. It may be that the 
heterogeneity present in breast cancer specimens in vivo is 
not present in vitro. 
Once a cell line has been established, it is necessary 
to document that this cell line indeed consists of breast 
cancer cells, which are epithelial in origin. In a recent 
comprehensive analysis of 47 reported human breast cancer 
cell lines at the NCI, only 22 were human, non He-La cells 
(a frequent contaminant) with epithelial morphology, i.e. 
possessed three structural markers under the electron 
microscope: desmosomes, tonofibrils and intracytoplasmic 
ductlike vacuoles. Among those 22 were the MCF-7 and T-47-D 
\ 
■ 
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cell lines, confirming their reputation as 
well-characterized cell lines (57). One important criterion 
of these cells is the presence of sex steroid hormone 
receptors, as well as its concomitant, hormone 
responsiveness. In the case of MCF-7 cells, this would mean 
that the cells possess estrogen receptors and be responsive 
to hormonal manipulation, i.e., cell growth rates should 
respond to estrogens and antiestrogens. McGuire's group has 
undertaken a steroid receptor analysis of several human 
breast cancer cell lines, and found that the estrogen 
receptors in the cell lines tested were predominantly within 
the nucleus; in solid tumors, receptors are 
characteristically located in the cytoplasm (110) . By 
contrast, only 1 of 9 breast cancer cell lines contained 
cytoplasmic estrogen receptor. Moreover, when nuclear 
estrogen receptor was assayed, it was found that 5 of 9 cell 
lines had significant unfilled nuclear estrogen receptor. 
They postulated that this apparent translocation of the 
estrogen receptor into the nucleus might be attributable to 
"tissue culture conditions." It is important to note that 
the two MCF-7 strains tested, each obtained from different 
laboratories, were significantly different, in that one was 
cytoplasmic ER-postitive, the other cytoplasmic ER-negative 
and both were nuclear ER-positive. 
This discrepancy may reflect an important limitation in 
receptor research using human breast cancer cell lines: 
although the two MCF-7 strains were presumably from an 
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identical source they subsequently developed different 
characteristics accounting for inter-laboratory variation. 
It is necessary to examine carefully what is meant by 
"estrogen receptor positive," since the methods used for 
isolating cytoplasmic and nuclear estrogen receptor differ. 
Briefly, McGuire's group utilized a sucrose density 
gradient technique (See "Methods Section"). First, 100-fold 
excess unlabeled diethylstilbestrol (DES) was added to the 
sample and control tubes, then (3H) estradiol added to the 
sample, followed by a centrifugation step with 
dextran-coated charcoal to absorb free steroid. A sucrose 
density gradient centrifugation step further purified the 
protein, which was measured by the Lowry method (74). 
Nuclear receptors, on the other hand, were obtained by a 
protamine sulfate precipitation, a competetive binding assay 
similar to the one used for cytoplasmic receptors using a 
phosphate buffer extraction. It is notable that when 
nuclear estrogen receptor and not just cytoplasmic receptor 
was considered, the percentage of tissue culture cells that 
were ER-positive approximated those of solid tumors (5/9 vs. 
50-60%, respectively). Moreover, all cell lines which had 
measurable nuclear estrogen receptor also had cytoplasmic 
estrogen receptor, while the converse did not always apply. 
It would seem, therefore, that the assay for nuclear 
estrogen receptor more accurately reflects the estrogen 
receptor status of the whole cell when human breast cancer 
cell lines are assayed. For solid tumors, this is not 
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necessarily the case. 
Another disconcerting aspect about cell culture is that 
if the growth medium is not selected to mimic in vivo 
conditions, it is conceivable that certain populations of 
cells might be selected which will thrive in the new in 
vitro enviroment. This might explain why the 
androgen-sensitive breast cancer cell line in Yates' 
laboratory lost its sensitivity to androgens when cultured 
in a testosterone free medium (159) . This possibility has 
been minimized in the MCF-7 and T-47-D breast cancer lines, 
which are routinely grown in an estradiol- containing medium 
(see "Methods Section"). 
A few words about basic cell kinetics are relevant when 
one is searching for synergy between drugs. The continuous 
cell cycle can be conveniently divided into four stages 
(Fig. 4): G1, S, G2 and M. During G1, or the "first gap 
phase," cells which have just divided and begin to grow 
synthesize RNA and protein, but not DNA. In the S phase 
they begin to produce both DNA and histones for chromatin, 
while continuing to grow. During S phase, the synthesis of 
protein and RNA continues until G2, the second growth phase, 
where DNA and histone synthesis stops, and baseline protein 
RNA synthesis continues. The cell continues to grow until 
M, or mitotic phase, when cell growth and all production of 
protein and RNA cease. 
In culture, cells do not grow synchronously — there 
are an unpredictable number of cells in any given phase, 
■ 
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though at any given time far fewer in the M Phase, since 
temporally this is the shortest phase. It is an 
interesting, and apparently a clinically very significant 
phenomenon, that cells in culture can be transiently 
synchronized to a particular growth phase by the use of 
cycle-specific agents, thereby maximizing the effects of 
drugs which act only during particular segments of the 
growth cycle. Necessarily, cytotoxic agents cannot be 
applied through the complete cycle of all cells at maximal 
doses, since associated toxicity to normal, non-target cells 
would be prohibitively high. 
Another important aspect of cell growth kinetics is the 
growth pattern of cells in culture. Measured simply as 
number of cells/ml, there are three phases of growth: the 
latent phase, after cells have been seeded into a flask and 
before they grow in large numbers; the logarithmic phase, 
where numbers of cells increase exponentially until either 
limited space, low pH or inadequate nutrient media limit 
growth; and the final plateau phase (see Figure 5). 
Although cells are not growth cycle synchronized, there 
are several patterns of metabolism which have relevance to 
the effectiveness of chemotherapeutic agents. Also, 
biochemical measurements which do not take these kinetics 
into account may be spurious. To demonstrate this Benz and 
Cadman measured several biochemical parameters in L-1210 
cells, a murine leukemic cell line. They found that during 
the midportion of logarithmic growth in this cell line, 
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incorporation of glycine into purine bases, intracellular 
phosphoribosyl pyrophosphate (PRPP) pools and 
deoxyribonucleotides, the building blocks for nucleotide 
synthesis (Fig. 1), began to decrease significantly, as did 
cell volume. The amount of DNA per cell, however, did not 
change appreciably. As one might expect, the products of a 
rapidly growing cell, namely RNA, protein content and 
ribonucleotides all increased during mid-log phase; however 
they fell off sharply during late logarithmic-early plateau 
phase (18) . The relevance of these phenomena to metabolism 
of various chemotherapeutic drugs is exemplified below. 
Benz et al demonstrated with the human colon carcinoma cell 
line, HCT-8, that cells synchronized with deoxythymidine 
(which causes an arrest at the Gl-S phase boundary), were 
resistant to the 5-FU during the following G2/M phase (20). 
Lastly, it is noteworthy that a cell type may also 
metabolize an active compound into several other species, 
which in turn have variable biological effects. The MCF-7 
line, for example, produces both estrogens and androgens, 
such as dehydroepiandosterone and testosterone (128) . 
■ 
CHAPTER III 
SCATCHARD ANALYSIS 
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Scatchard Plot of Equilibrium Substrate Binding 
Data Applied to Estrogen Receptor Analysis 
[S]b= concentration of bound ligand (i.e. concentration of 
estrogen-receptor complexes) 
[S]f= concentration of free ligand 
[E]t= total concentration of enzyme (i.e. concentration of 
estradiol) 
n= number of identical and independent ligand binding sites 
per molecule of enzyme 
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Therefore: 
n[E]t= total concentration of ligand binding sites (i.e. total 
estrogen receptors) 
Ks= ligand concentration at which the reaction rate is at 
half its maximal value (i.e. concentration of estradiol 
at which half the estrogen receptors are saturated; the 
lower the value, the greater the affinity of the receptor 
for its hormone) 
Derived from the equation: 
JS.lb =r2_L£lt> +nIEli 
[S]f Ks Ks 
Using this method of calculating affinity of substrate for 
receptor, as well as total number of binding sites, leads Benz 
(114) and Yang (158) to conclude that 5-FU treated MCF-7 cells 
have less estrogen receptor with identical affinity for estradiol 
when compared with control MCF-7 cells (Discussion Section). 

CHAPTER IV 
HORMONAL CONTROL OF CANCER 
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The treatment of breast cancer by hormonal manipulations is 
not new; as early as the end of the last century, advanced 
carcinoma of the breast was palliated by ovariectomy. 
Surgery, and later radiation were used to ablate these 
estrogen-producing structures, yet the rationale for this 
procedure was simply that the incidence of breast carcinoma 
was much higher in females than males (62). 
Experiments in 1936 on a strain of mice with a 
propensity to develop breast carcinoma showed a much higher 
female incidence. Yet when male rats were administered 
estrogen, they demonstrated pre-cancerous cell types, and 
eventually metastatic breast adenocarcinoma. Similarly, in 
a strain of mice with a low natural incidence of breast 
carcinoma, administration of high doses of estrogen yielded 
tumors in nearly all the mice tested (95). 
In prostatic cancer, hormonal therapy, particularly 
with DES, provides excellent palliation; estrogen therapy 
also provides an alternative for men not permitting 
orchiectomy. Therapy with the anti-androgen cyproterone 
acetate (Androcur) has been disappointing, despite its 
theoretical promise. In fact, hormonal therapy is the main 
treatment modality for advanced prostatic cancer. At least 
80% of the cases will respond for varying periods of time to 
hormonal therapy (55). Gustafsson and his group in Sweden 
correlated clinical response rate in prostatic cancer 
patients with tumor androgen receptor status (68) . Of 16 
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patients whose prostatic tumors were assayed for estrogen 
receptor, 9/11 who had measureable receptor levels responded 
well (82%), while those without measureable receptor levels 
responded poorly (1/4 = 25%) . Notably, the two 
receptor-positive individuals who did not respond to 
hormonal therapy had the lowest detectable levels of steroid 
receptor. Gustafsson's group is quick to point out, 
however, that although the correlation between estrogen 
receptor positivity and clinical response was excellent, the 
results were not performed in an isolated system; it is 
therefore possible that the estrogen therapy administered 
acted via a negative feedback loop on the luteinizing 
hormone secretion of the pituitary gland resulting in 
decreased testicular secretion of testosterone, and 
therefore less androgenic stimulation to the prostate. 
Endometrial cancer responds well to progestins in a 
third of all cases. This well-documented phenomenon is most 
closely correlated, as one might imagine, with the presence 
of progesterone, as well as estrogen receptor. Estrogen 
receptors may be necessary for synthesis of progesterone 
receptors. 
Renal cancer also shows promise of responding to 
androgens or progestins in small clinical trials (148). 
Concolino's group demonstrated that 61% of human renal cell 
tumors tested had estrogen receptor, and 61% had 
progesterone receptor. After nephrectomy, 18 patients 
received progestational therapy; in 14 of them, objective 
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benefit was noted (47). Others have reported success using 
adrenal cortical hormones, testosterone and progesterone 
(48), in both laboratory animals and man. 
The discovery that some tumors traditionally thought 
not to be endocrine responsive may actually contain hormone 
receptors and respond to endocrine therapy raises many new 
therapeutic possibilities. Specifically regarding 
pancreatic cancer, Greenway's group has found that 
pancreatic cancer cells contain high affinity binding sites 
for estrogen, presumably estrogen receptors. Moreover, they 
found similar receptors in fetal but not in normal pancreas, 
suggesting derepression of fetal genes might be occurring 
with pancreatic cancer(66). Benz et al have reported on the 
in vitro sensitivity of pancreatic carcinoma cell lines to 
TAM, suggesting the presence of estrogen receptor. More 
exciting is the possibility of combining hormonal with 
endocrine therapy to treat pancreatic carcinoma (26). 
(Figure 13). For example, the pancreatic cancer cell line, 
COLO-357, is sensitive to estradiol, tamoxifen and 
progesterone in vitro (21) (Figure 13). This cell line 
contains estrogen receptor; however, by Scatchard analysis 
its Kd is greater (hence its estrogen receptor has a lower 
affinity for estrogen) than the Kd for ER measured in the 
MCF-7 human breast cancer cell line (Figure 14). 
Estrogen receptors have been identified in numerous 
other tissues, such as malignant melanoma, colon carcinoma, 
gallbladder carcinoma, liver carcinoma, squamous cell 
. 
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carcinoma and even some sarcomas (147). Clinical studies 
have not yet been performed to evaluate the possibility of 
incorporating endrocrine therapy into the treatment programs 
involving those tumor types, although the possibilities are 
vast. 
Because of their ability to reduce mitosis in 
lymphocytes and destroy lymph tissue, adrenal steroids have 
been, and currently are being used to treat malignant 
lymphoma and leukemia. Numerous studies have shown a 
correlation between glucocorticoid receptors and clinical 
response to glucocorticoid therapy in non-Hodgkins malignant 
lymphoma (27) , acute lymphoblastic leukemia (ALL) and 
thymoma (78) , and lysis of both normal and malignant 
lymphoid cells (73). Using cytoplasmic extracts from 
lymphoblasts, Lippman and his group used a competetive 
binding assay similar to the one described in this thesis, 
("Methods Section") with [3H] dexamethasone, to determine by 
Scatchard analysis the number of specific glucocorticoid 
binding sites and a Kd of 2-8nM (104) . 
While the effects of estrogen upon breast cancer cell 
lines (stimulatory) and glucocorticoid upon lymphoblast cell 
lines (inhibitory) are opposite, they seem to exhibit a 
similar cause-and-effect relationship between hormone action 
upon a specific receptor, and the corresponding metabolic 
consequence (160) . Although the tumor growth patterns are 
not as clearly delineated as in breast carcinoma, there seem 
to be parallels both in the remissions and patterns of 
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resistance (160) . 
Similarly, when corticosteroid therapy is employed 
concomitantly with an antimetabolite such as vincristine, 
more satisfactory clinical remissions are evident; in breast 
cancer, combined chemo- and endocrine therapy shows great 
promise in both in vitro and clinical trials (115, 3). 

CHAPTER V 
HORMONES IN BREAST CANCER 
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Hormone withdrawal therapy has found a secure place in 
the treatment of breast cancer. Ovariectomy, preferably 
surgical because of its faster induction of remission, had 
been advocated as the primary treatment for premenopausal 
women with inoperable advanced breast cancer. The clinical 
response rate varies between 10% and 35%, and lasts 10-25 
months on the average (148) . 
Regarding the commonly employed androgens used to treat 
disseminated breast cancer, regimens frequently include 
pharmacologic doses (much larger than needed for 
physiological function) of fluoxymesterone, calusterone and 
droomostanolone proprionate (62, 148). Testosterone 
propionate and testosterone enanthate, though clinically as 
effective as the other androgens, have unacceptably 
virilizing effects. Progestins, androgens, medical or 
surgical hypophysectomy or adrenalectomy (eg. 
aminoglutethamide) are endocrine agents of last resort. 
Response rates vary greatly, from 20-25% for androgens and 
progestational agents, to 30% with adrenalectomy. 
Paradoxically, estrogens themselves have found a place 
in treating breast cancer. The therapeutic regimen most 
frequently DES and ethinyl estradiol have been employed 
successfully. Traditionally, endocrine therapy is continued 
for 8 to 12 weeks, at which time progress is evaluated. If 
the tumor appears to have responded, therapy is continued 
until a recrudescence is evident. Interestingly, after this 
has occurred and endocrine therapy is then stopped, another 
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remission frequently ensues, suggesting that a population of 
tumor cells dependent upon the pharmalogical doses of 
estrogen has developed. 
The response rate to DES therapy approaches 30-40% of 
all postmenopausal patients treated, with the length of 
remissions lasting from 6 months to 1 year. 
Recently, tamoxifen has replaced DES as the initial 
treatment for patients who are more than 5 years past the 
menopause (148). The dosage generally employed is around 
20-40 mg daily. A regression in tumor size of >50% has been 
noted in 30%-40% of patients treated for 12-24 months (148). 
It is now clinically well-established that patients 
with breast tumors containing measureable levels of ER 
respond better, and with greater frequency, than patients 
without detectable estrogen receptor levels (81). The 
response rate for ER-positive tumors to endocrine therapy is 
60% compared to 10% for ER-negative tumors. Roughly half of 
tumors assayed are found to be ER-positive (130). 
There are very few studies which dispute the importance 
of ER status. Leake's group in Scotland reported finding 
estrogen receptors in only 1 of 72 tumors sampled. Their 
finding that none of the 25 patients with advanced breast 
cancer who were treated with tamoxifen responded clinically, 
suggested to them that breast cancer did not contain ER 
(98) . In this particular study, no effort was made to 
quantitate ER by Scatchard analysis. Instead, Leake used a 
one-spot competetive binding assay introducing a possible 
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source of error which he acknowledged. 
Although, patients with breast cancer generally respond 
best to endocrine therapies if their tumor specimen contains 
ER, this correlation is not perfect. A better correlation 
is obtained by assaying both estrogen and progesterone 
receptor (PGR). McGuire's group noted that response rates 
for patients with ER levels of <3, 3-100 and 101-1000 
fmol/mg cytosol protein was 6%, 46% and 80%, respectively 
(111). This represents a better correlation than the often 
quoted figures of 10% and 60% response rates for ER-negative 
and ER-positive tumors. When ER status is noted as either 
positive or negative, and PGR status is also considered, 7 
series of patients are compared, with the following results 
(111), indicating partial responses. 
ER-negative 
PGR-negative 
9/63 = 14% 
ER-positive 
PGR-negative 
20/71 = 28% 
ER-negative 
PGR-positive 
(3/6 = 50%) 
ER-positive 
PGR-positive 
67/91 = 74% 
Ratios shown indicate the number of patients in 
category (numerator) over the total number of patients 
tested (denominator). Patients in the ER-negative, 
PGR-positive group are in parentheses to indicate the small 
sample size. It is noted that some ER-negative, PGR- 
negative samples may spuriously be PGR-negative; it is known 
■ 
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that progesterone receptor synthesis is estrogen dependent 
(75), and that in ER-negative tumors, the PGR may be 
unexpressed. Thus, it might be considered feasible to give 
women a small dose of estrogens prior to the assay for PGR 
(75) . 
Israel and Saez have noted another limitation: they 
have found that in women who had plasma progesterone levels 
higher than 100 ng/lOOml, the determination for PGR was 
invariably negative; possibly, progesterone has inhibited 
the production of its own receptor in a negative feedback 
loop (79) . Estrogen receptor status alone remains a more 
clinically important prognosticator than age, menopausal 
status or nodal status alone in women with operable breast 
cancer (90) . McGuire found a correlation between menopausal 
status, ER status, and clinical response to chemotherapy: 
premenomenopausal women seem to develop more aggressive, 
ER-negative tumors which respond poorly to endocrine therapy 
(this would be predicted by the ER-negative status), and yet 
retain their responsiveness to chemotherapy. This can be 
explained because such tumors grow more quickly, have a 
higher growth fraction (112), and, accordingly, are more 
susceptible to the antimetabolites active against rapidly 
dividing cells). 
Allegra and Lippman's group have made another 
observation -- that the presence of estrogen receptor 
correlates with a poor response to chemotherapy. In a 
retrospective study, 34/45 (76%) of women with ER-negative 
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adriamycin alone or in combination with other agents (2) . 
Most regimens contained 5-fluorouracil. This observation is 
intuitively surprising, but is in good accord with McGuire's 
previous observation that tumors with estrogen receptors are 
slower growing than their ER-negative counterparts. It 
seems logical that a tumor without detectable estrogen 
receptor is phenotypically more divergent from the 
differentiated cell type that makes up normal breast 
epithelial tissue; these anaplastic tumor cells might 
therefore be more rapidly growing. The opinion that 
ER-positive tumors respond worse to chemotherapy than 
ER-negative tumors is by no means uniform; there are also 
several studies suggesting that ER-positive tumors respond 
better, (28, 89) or at least the same (28) as ER-negative 
tumors. 
In a recent review of the literature, almost every 
series has shown that women with ER-positive tumors have 
better survival and 3-year relapse-free survival rates than 
ER-negative patients (28). Conversely, postmenopausal women 
have more ER-positive tumors, which respond better to 
hormonal therapy and worse to chemotherapy. 
These observations are so well substantiated that many 
investigators have recommended categorically that every 
woman with breast cancer should have estrogen receptor 
assays performed (111). The data, in total, suggest that 
most premenopausal women with breast cancer have less 
differentiated, more anaplastic, ER-negative tumors, which 
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most premenopausal women with breast cancer have less 
differentiated, more anaplastic, ER-negative tumors, which 
are probably best treated with chemotherapeutic regimen. 
Postmenopausal women, on the other hand, tend to have less 
undifferentiated, slower growing tumors which respond best 
to hormonal therapy. 
Correlating receptor status with tumor cytokinetics, 
Allegra and others have suggested it is theoretically 
possible to arrest cells in one uniform stage of the cell 
cycle by means of antiestrogens. It would then be possible 
to advance cells synchronously by means of estrogens, and 
use of an S-phase specific chemotherapeutic agent when the 
cells enter S-phase, resulting in maximal tumor cell 
cytotoxicity with the lowest possible dose of 
chemotherapeutic agent (2). 
Kute and Wittliff have shown that there exists a 
correlation between clinical response and a certain 
molecular form of estrogen receptor. Estrogen receptor 
separates into 4S and 8S components when sedimented on a 
linear sucrose gradient. Women with tumors containing the 
8S form were more likely to respond to hormonal therapy. 
Each separate form (i.e. 8S, 4S) has several specific 
estrogen binding components. Those components elute out at 
different ionic strengths on diethylaminoethyl (DEAE) 
cellulose columns. Wittliff's group has postulated that the 
8S aggregate is necessary for normal activation of the 
estrogen receptor, and that its apparent components. 
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would predictably not be responsive to hormonal therapy 
(94) . 
Accordingly, when patients who were ER-positive but 
whose receptor did not demonstrate the 8S species were 
eliminated from consideration, the response rate to hormonal 
therapy rose to 75% (as compared to the frequently cited 
figure of 55-60%) (94). 
It is conceivable that amidst all tumors there is a 
heterogeneous population of cells, some of which contain 
estrogen receptor and will respond to hormonal therapy, 
while still other cells will remain resistant to hormonal 
therapy because of deficient or absent estrogen receptor. 
Such tumor heterogeneity may await the selective forces that 
will favor the eventual preponderance of a resistant cell 
type. 
The interrelations between the estrogen receptor and 
other hormones are complex and poorly understood. It is 
known that tumors containing positive ER and PGR respond to 
hormonal therapy, and, predictably, are stimulated by 
estradiol. These tumors are also stimulated by insulin. On 
the other hand, tumors containing only ER, or neither ER nor 
PGR, do not respond to estradiol plus insulin(79). PGR, 
then, seems to signify the presence of a properly 
functioning ER. 
In certain breast cancer cell lines, prolactin either 
stimulates or maintains ER. Estrogens, on the other hand, 
interfere with prolactin binding (71) . Insulin seems to 
■ 
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regulate ER (71). Indeed, insulin has been implicated in 
mammary tumorigenesis (70). Estrogens, on the other hand, 
seem to decrease binding of insulin (71, 141), probably by 
reducing the number of insulin receptors. An interesting 
correlate can possibly be seen in women taking 
estrogen-containing contraceptives as during early 
pregnancy, in whom glucose tolerance abnormalities have been 
noted. Is this a manifestation of downregulation of insulin 
receptors? 
Other studies have demonstrated an interaction between 
cyclic adenosine 31s 5' monophosphate (cAMP) and estrogen. 
Rat mammary carcinomas show increased cAMP binding and 
decreased estradiol binding if the hosts are treated either 
with DBcAMP (N6,02-dibutyryl cyclic adenosine 3' : 
5'-monophosphate) or with ovariectomy. Furthermore, these 
changes were reversible either with exogenously administered 
estradiol or cessation of DBcAMP treatment (38). This study 
suggests that an antagonistic action between estradiol and 
cAMP exists in rat mammary carcinomas. 
Recently, some exciting studies have come out 
demonstrating the presence of receptor proteins for cAMP. 
It seems that there exist at least three subtypes, with 
molecular weights of 39,000, 48,000 and 56,000 daltons. The 
39,000 dalton segment is most probably a fragment of one of 
the larger subunits, each of which is probably a protein 
kinase (cAMP-dependent protein kinase I and II, 
respectively). The association of charge alteration (as 
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determined by 2-d gel electrophoresis) with hormone 
independency has been noted in mammary tumors in rats (39) , 
and the question of an association between cAMP receptors 
and steroid dependency of human has been tumors raised. 

CHAPTER VI 
TAMOXIFEN (TAM) 
(Figures 3, 6, 10) 
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The use of antiestrogens to treat hormone-dependent 
malignancies is intuitively appealing. Its actions may be 
specific for ER (131), the site of the action of estrogens, 
which have been shown to promote the growth of mammary 
carcinomas and breast cancer cell lines, especially in those 
with high levels of estrogen receptor. After oral 
administration, peak concentrations of tamoxifen occur in 
4-7 hours. It undergoes extensive metabolism, in particular 
to a monohydroxylated (OH-TAM) derivative that has even more 
antiestrogenic properties than tamoxifen itself (this 
property is experimentally important; discussed later). Its 
metabolism is enterohepatic, and its metabolites are 
excreted in stool. Its final Tl/2 is at least 7 days (62). 
Tamoxifen is a relatively poor binder to estrogen receptor; 
its Kd is from 30 to 300 times as high as the Kd for 
estradiol binding. However, OH-TAM (as assessed by its 
radioactive form (3H) OH-TAM), binds as well to estrogen 
receptor as estradiol (46). TAM provides an attractive 
alternative to surgical ovariectomy, which is invasive and 
does not completely eliminate the available source of 
estrogens. Antiestrogens, on the other hand, attack the 
effector site. Thus, it may be irrelevant that peripheral 
estrogens continue to be produced by adipose tissue and the 
adrenal medulla. 
The systemic toxicity of antiestrogens in general, and 
tamoxifen in particular, is low (100). Serious toxicity is 
usually restricted to hot flashes, nausea, vomiting, and 
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various other minor side effects, all of which seldom 
necessitate stopping therapy: only 25% of patients treated 
have these adverse effects. Less frequent side effects 
include menstrual irregularities, vaginal bleeding and 
discharge, pruritis vulvae and dermatitis (62), probably 
representing withdrawal effects of estrogen from these 
tissues. The usual dosage of TAM is 20 to 40 mg daily. 
Responses may be paradoxically associated with inflammation 
and increase in the size of lesions, as well as bone pain at 
the site of metastases, and usually occur in 4-10 weeks 
(62) . 
Antiestrogens may also effect a reduction in binding of 
prolactin to mammary tumors, reducing the effects of another 
factor which may enhance tumor growth (84). 
It was once believed that antiestrogens acted by 
binding to the estrogen receptor, effectively rendering it 
unavailable for estrogen. The full story is a considerably 
more complicated, however. Indeed, antiestrogens may 
prevent estrogens from expressing themselves, and most 
probably, they act through the estrogen receptor (131). 
Evidence suggests that antiestrogens have several cellular 
effects. They compete with estrogens for formation of a 
receptor-steroid complex; they alter binding to the nuclear 
binding sites; and may even disrupt the regeneration of the 
cytoplasmic receptor (82). Importantly, they must bind to 
ER and enter the nucleus in order to bind to chromatin and 
induce their effects. But the specifics of the process from 
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this point on are not clear. 
Katzenellenbogen has found that the TAM-ER complex is 
translocated to the nucleus. Usually, this event occurs 
identically with estrogens and antiestrogens, but with 
estrogens, the level of cytoplasmic receptor is replenished 
relatively soon after exposure: in the case with 
antiestrogens, the antiestrogen-receptor complex is retained 
for prolonged periods in the nucleus and the level of 
cytoplasmic receptor is depleted for prolonged periods (41). 
Moreover, experiments on estrogen-responsive uterine 
tissue showed that the uterus was refractory to the effects 
of estrogens during the period where cytoplasmic receptors 
were depleted. And estrogen responsiveness returned 
linearly with the return of cytoplasmic estrogen receptor 
levels (84). This relationship is dose-dependent, that is, 
the higher the dosages of antiestrogens the greater the 
antagonism of the actions of estrogens. It is unknown why 
an antiestrogen can exert its effects at levels so low that 
no depletion in cytoplasmic receptor can be detected at all. 
By depleting cytosolic ER, an antiestrogen can render 
an estrogen-dependent tumor cell incapable of growing. 
Whether this reflects a decrease in the synthesis of 
estrogen receptor (45) or, more probably, a sequestration in 
the nucleus is not fully clear (84) . There is a small body 
of evidence suggesting TAM has its own receptor, similar to, 
but separate from the estrogen receptor (150) . Some 
antiestrogens, most of them investigational agents, have 

43 
been found to act through a mechanism different from the 
estrogen receptor (15). 
The effects of antiestrogens on thymidine utilization 
have also been studied. Estrogen treatment of MCF-7 cells 
increased total cellular thymidine synthesis two to 
threefold, but tamoxifen treatment reduced total thymidine 
synthesis by 15 to 30% below control rates. The rate of 
extracellular salvage uptake of dThd increased initially, 
but decreased significantly after 24-48 hours. There is a 
marked shift in TAM-treated MCF-7 cells toward the salvage 
pathway, accounting for 60-70% of the total thymidine 
production (compared to 5% for estrogen-treated MCF-7 
cells). It would seem, therefore, that tamoxifen disrupts 
the de novo pathway preferentially (105). 
The effect of TAM treatment is an overall reduction in 
intracellular dThd pools (105), and a resultant inhibition 
of DNA synthesis. Overall tamoxifen treatment results in 
decreased DNA, RNA and protein synthesis, as one would 
expect (53) . TAM has been noted to have an effect on 3Urd 
incorporation into RNA. Specifically, TAM increases the 
radioactive nucleotide's incorporation into the <4S segment 
of RNA (23). 
Tamoxifen cytotoxicity has its correlate in the cell 
cycle. It produces a decrease in S-phase cells and an 
accumulation of G1 phase cells. When tamoxifen is 
withdrawn, the cells can be synchronized (19). This will be 
useful later in showing TAM- 5-FU synergy is not based on 
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synchronization of cells alone. 
Recently the question has arisen whether TAM is also 
acting through a completely different, calmodulin-related 
mechanism. An article, which appeared in the 1984 Proc. 
Natl. Acad. Sci. (113), showed that a phosphorylation 
reaction of tyrosine residues is necessary for hormone 
binding to estradiol receptor, a step catalyzed by a protein 
kinase. Ca++ and calmodulin can stimulate estradiol binding 
in the presence of this protein kinase. It is also known 
that TAM may have an inhibitory effect upon calmodulin (96), 
which may in turn slow the Ca++-augmented protein kinase 
reaction necessary for receptor activation. 
The structure of the antiestrogen-receptor complex is 
remarkably like the estrogen-receptor complex. On sucrose 
gradient centrifugation, the complexes are indistinguishable 
(82). Antiestrogens appear to have a very long in vitro 
half life — 18-24 hours, compared with 1/2 hour in the case 
of estradiol (82). 
As is the case with other drug antagonists, 
antiestrogens are by no means solely antagonistic to 
estrogens. However, their agonistic properties are, by 
definition, limited. The long-term retention in the nucleus 
of estrogen receptor can have corresponding long-term 
stimulatory effects, especially on uterine tissue (155, 43) 
(Figure 6). In spite of being bound longer to the nucleus, 
however, TAM-ER does not induce typical estrogen mediated 
effects (92) . 
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Thus, it is known that TAM binds to ER, and that the 
complex is translocated to the nucleus. Benz, Cadman and 
coworkers have found that the effects of TAM upon the 47-DN 
human breast cancer cell line are completely reversible in a 
dose-dependent fashion with luM estradiol administration. 
Its effects become irreversible if estradiol is not 
administered within 48 hours (19). It is unlikely that 
TAM's effects are cell-membrane mediated. Benz has found 
that the human osteogenic sarcoma cell lines MG-63 and 
G-292, which have no measureable ER, were not inhibited by 
TAM at doses of less than 10 uM. However, above this 
concentration, cell growth was inhibited by 20-30%. But 
this growth inhibition could not be reversed with estradiol 
administration, nor was it synergistic when 5-FU was 
administered along with the TAM (13). 
These data suggest TAM's effects are not cell membrane 
mediated at concentrations of less than lOuM, but are at 
concentrations above this. At least initially, presumably 
when TAM binds to ER, estradiol is able to reverse the 
TAM-induced cytotoxicity, but not thereafter. 

CHAPTER VII 
FLUOROURACIL (5-FU) 
(Figures 1, 4, 10) 
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5-FU has seen wide clinical use. It is of at least 
palliative benefit with several types of cancer, 
particularly with neoplasms of the breast and 
gastrointestinal tract, pancreas, ovaries, cervix, bladder 
and head and neck, as well as in dermatological 
preparations. 
Unfortunately, clinical toxicity is formidable, and 
limits the dosage of drug possible. The value of combining 
it with another drug with less systemic toxicity, 
particularly if the combination were synergistically toxic 
against cancer cells, is obvious. 
Indeed, 5-FU has numerous clinical toxicities. 
Anorexia, nausea (78-90%) and vomiting (50-65%) are common, 
and frequently precede diarrhea (34-85%) and stomatitis 
(63-75%). When these clinical symptoms supervene, the 
correct dosage has been attained. It is clear from those 
symptoms that the primary actions of 5-FU are upon rapidly 
dividing tissues, especially in the gastrointestinal tract, 
oral mucosa, but also in the bone marrow. Leukopenia, 
thrombocytopenia, anemia, loss of hair and atrophy of the 
skin are also common (62, 32). The typical dosage is 
12mg/kg per day for four days, followed by 6mg/kg every 
other day up to a theoretical maximal daily dose of 800 mg. 
Classically, it is thought that 5-FU acts as an 
inhibitor of the enzyme thymidilate synthetase, the enzyme 
which converts dUMP to dTMP. Inhibition of DNA synthesis is 

48 
mediated primarily by one of 5-FU's metabolites, FdUMP 
(134) . 
It now seems that there are many important mechanisms 
accounting for 5-FU's cytotoxicity. Briefly, its toxicity 
can be categorized as membrane-directed, DNA-directed, and 
RNA directed, depending on the actions of its many 
metabolites (Fig 1) . 
Its DNA-mediated toxicity is mediated by 
5-fluorodeoxyuridylate (FdUMP). Experimentally, the 
compound florodeoxyuridine (FdUrd, FUDR) is metabolized 
primarily into FdUMP by a phosphorylation reaction. It is 
useful experimentally to assess the DNA-directed component 
(i.e. by inhibiting thymidylate synthetase and subsequent 
DNA formation). Surprisingly, it was discovered that the 
main effects of 5-FU are not DNA-mediated but RNA-mediated 
(25). Cory's group concurred, finding no significant 
inhibition of thymidylate synthetase (50). 
The RNA-mediated effects of 5-FU are primarily mediated 
through fluorouridine triphosphate (FUTP). The 5-FU-related 
compound used experimentally to obtain maximum RNA-directed 
cytotoxicity is 5-fluorouridine (FUrd). It is 
phosphorylated to FUMP, another metabolite of 5-fluorouracil 
which is preferentially incorporated into RNA. This is a 
very important aspect of the cytotoxicity of 5-FU, and will 
be commented upon later. 
Another relatively less important source of 
cytotoxicity of 5-FU is 5-fluorouridine diphosphate: 
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glucose, which has its primary effects upon the cell 
membrane (87). 
The cytotoxicity of 5-FU has its correlates in the cell 
cycle. One might expect its DNA-directed effects (through 
FdUMP) to show S-phase (i.e. when DNA synthesis takes place) 
specificity (20) . In the HCT-8 colorectal adenocarcinoma 
cell line synchronized with dThd, the amount of FdUMP 
generated, 5-FU incorporated into cells, and 5-FU 
metabolites incorporated into RNA did not demonstrate a cell 
phase specifically correlating with either G1, S, G2 or M 
phase. There was, however, slight G2/M resistance. 
The RNA-directed effects of 5-FU metabolites warrant 
particular attention. The evidence that incorporation of 
5-FU metabolites into RNA correlate with less of clonogenic 
survival is overwhelming in the MCF-7 line. Kufe and Major 
demonstrated that this relationship is highly significant (p 
< 0.0001), dependent upon both time and concentration. The 
widely accepted mechanism of action previously proposed by 
Santi and McHenry (134), namely that 5-FU bound irreversibly 
to thymidylate synthetase, decreasing DNA synthesis, is 
challenged with the finding that when thymidine is 
administered to MCF-7 cells in culture and the thymidylate 
synthetase step in pyrimidine biosynthesis bypassed, 
cytotoxicity is not reversed. This suggests that the 
FdUMP-mediated cytotoxicity of 5-FU is not a critical 
mechanism. 
These results were obtained utilizing cesium sulfate 
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gradients, which permit separation of RNA and DNA into 
separate bands, allowing one to compare the relative 
contribution of radiolabeled nucleotide to each fraction. 
The effects of 5-fluorouracil upon cellular RNA have 
been measured. Every species of RNA incorporates 5-FU 
metabolites to some extent. But it is its incorporation 
into RNA that precedes abnormal protein synthesis, probably 
because the secondary structure of RNA is altered and base 
modification is impaired (96). In particular, uridine 
derivatives in RNA molecules are reduced, reflecting a 
significant substitution of uridine by 5-fluorouridine 
(152) . This in turn has a direct effect on the enzyme 
uracil 5-methyltransterase, an enzyme whose activity is 
significantly elevated in malignant tumors (146, 150). The 
incorporation of 5-fluorouracil appears to occur into mRNA. 
Polyadenylation step of mRNA is impaired, and production of 
mature mRNA is decreased (64). 
Incorporation of 5-FU into polysomal RNA has been 
measured. The synthesis of poly (A) RNA — polyadenylic 
acid containing RNA — was unaffected by a moderate dose of 
5-fluorouracil (35). Data from sucrose gradient analysis 
and polyacrilamide gel electrophoresis show that the 32S - 
45S species of RNA (pre-ribosomal RNA) are reduced (50). 
Other investigators have shown that the formation of 18S 
ribosomal RNA is blocked — albeit by a combination inosine 
and 5-FU in a cell line otherwise unresponsive to the 
effects of 5-FU — resulting in altered maturation of 
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precursor rRNA (50). Overall, rRNA synthesis has been found 
to be decreased by about 60% (35) in experiments on liver 
tissue of rats. 
Unlike other chemotherapeutic agents (i.e. 
azacytidine). 5-fluorouracil is not believed to affect 
methylation of the 45S pre-rRNA or hnRNA (heterogenous 
nuclear RNA). Methylation reactions of LnRNA and tRNA were 
shown to be markedly reduced (154) . Nuclear methylation 
reactions are critically important to cellular function: 
they regulate the initiation of transcription, allow for 
ribosomal stability and acylation of amino acids — by means 
of the 4-8S RNA structure. The overall effect of the 
incorporation of 5-fluorouracil into RNA is an accumulation 
of defective LnRNA, and probably deficient protein 
synthesis. One species of LnRNA in particular, the 4-8S 
RNA, has been implicated in tamoxifen-5-fluorouracil 
synergy. 
It will be recalled that antiestrogens, in this case 
tamoxifen, resulted in reduced DNA, RNA and protein 
synthesis (53). The implications of this common denominator 
are especially exciting, and will be discussed along with 
the synergy of TAM and 5-FU. 

CHAPTER VIII 
ESTROGEN-RECEPTOR BINDING TO 
DNA-CELLULOSE 
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The binding of the estrogen receptor to tritiated 
estradiol complex (ER- (3H)E2) to the nucleus is affected by 
numerous factors, most prominent among them are various 
species of RNA, suggesting an autoregulatory circuit 
operating at the receptor level. Furthermore, the complex 
has selectivity in its binding, suggesting an ability of the 
estrogen receptor complex to recognize specific sites on 
nuclear template. But even before any binding can occur, 
the ER-E2 complex must be activated (121) . 
Several investigators have shown that RNA inhibits 
estrogen-receptor complex binding to DNA-cellulose. Sato's 
group demonstrated that dialysis of cytosol containing [3H] 
E2-ER complexes resulted in a 3 to 6-fold increase in 
nuclear binding of the complexes to nuclei in their 
cell-free system obtained from ovariectomized rat uterus. 
They postulated low molecular weight inhibitors which were 
normally present in the cytosol inhibited the binding of 
ER-E2 complex to the nucleus (137). It has been shown in 
other systems that certain poly- and oligonucleotides 
promote the release of androgen-receptor and rat uterine 
estrogen- receptor complexes from DNA-cellulose (101). Poly 
(U,G) nucleotides were particularly effective. Again, the 
relationship was shown not to be solely charge-dependent. 
These data are consistent with an estrogen receptor model 
having a relatively base specific "autoregulatory" binding 
site for RNA, perhaps important in establishing 
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post-transcriptional, negative feedback control loop. An 
excellent study in a rat mammary tumor model demonstrated 
that a high molecular weight inhibitor of estrogen-receptor 
complex binding to DNA-cellulose existed which was destroyed 
by RNase but not DNase. Moreover, when different 
polynucleotides were were tested for their inhibitory effect 
on binding, Feldman et al discovered that poly(G) and 
poly(U) were by far the most inhibitory species tested (61), 
in close agreement with Liao's results (101). Moreover, 4S 
RNA increased the inhibition while rRNA did not (61). More 
specifically, Poly(U) and Poly(G) were most able to release 
receptor complexes when the U:G ratio was 1:5. A minimum of 
15-20 nucleotides was necessary for activity (101) , from 
which one can infer that sequence specificity exists. 
Chong and Lippman performed similar experiments in the 
MCF-7 cell line and demonstrated that under low-salt (but 
not under high salt) conditions, RNA was associated with 
estrogen-receptor complexes. Moreover, purified RNA from 
MCF-7 cells inhibited estrogen-receptor complex binding to 
DNA-cellulose (40). Estrogen-receptor has shown a 
preference for A-T containing regions of double-stranded 
DNA. Yet the apparent correlation of increased electro¬ 
negativity of binding sites with binding does not hold, 
since tRNA does not compete for nuclear binding sites (88) . 
Another investigator, Dickerman at SUNY at Albany, has 
proposed a model based largely on these observations, as 
well as on his finding that DNA-cellulose has a preference 
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for dG and dT sites, suggesting nuclear template may have 
specific sites recognized by dG and dT sites on the 
estrogen-receptor complex, which are possibly quite 
important in receptor recognition of the appropriate binding 
sites necessary to initiate transcription. It seems that 
binding of receptor-steroid complex to DNA is a linear 
function, nonsaturable because of the great excess of 
nuclear binding sites. The affinity of the complex for DNA 
is relatively low (157). Importantly, the greater the 
binding to DNA, the greater the magnitude of the response 
(i.e. a "trigger" as "cascade" phenomenon does not apply). 
It is also quite possible that the effects of 
steroid-receptor complexes are mediated by just a few high 
affinity nuclear binding sites, as some recent data suggest 
(51) , and that their presence is masked by the overwhelming 
preponderance of low-affinity, nonspecific binding (157). 
This thesis presents results relating these phenomena 
to the synergy observed in vitro between 5-FU, which has 
been shown to inhibit certain aspects of RNA processing, and 
TAM, which binds to estrogen receptor and has its effects in 
the nucleus. 

CHAPTER IX 
ESTROGEN RECEPTOR MODEL 
\ 
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A considerable amount is known about the estrogen 
receptor. Upon sedimentation on linear sucrose gradients, 
it can be resolved into 8S and 4S species. It appears that 
only the 8S species has typical estradiol binding activity, 
although each species can be broken up by diethylaminoethyl 
cellulose (DEAE) chromatography into separate, smaller 
binding components (94). 
The estrogen receptor has been recognized as pivotal in 
stimulation of cellular growth and metabolism. A number of 
excellent reviews of this topic exist (i.e. 12, 44) The 
estrogen receptor will be discussed here only as it relates 
to TAM-5-FU synergy. 
In Scatchard analysis of estradiol binding to estrogen 
receptor, Clark et al found that the classical estrogen 
receptor has a Kd of 0.8nM for the high-affinity "type I" 
site, and a lower affinity (Kd = 30nM) "type II" site. 
There is evidence that the 8S region contains type II, and 
the 4S region type I binding sites (44). Zava and McGuire 
found specifically in the MCF-7 line that the cytosolic 
estrogen receptor (ERc) and the nuclear estrogen receptor 
(ERn) have high-affinity binding sites with different 
sedimentation characteristics. For ERc, Kd = 0.8nM, 
sedimentation coefficient 4S-5S on sucrose gradient analysis 
(161). Thus, it is the nuclear estrogen receptor that has 
the characteristics of the "classic" estrogen receptor. The 
modern view of the different subunits of the estrogen 
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receptor is that the cytoplasmic estrogen receptor sediments 
at ~8S on sucrose gredients (or if deaggregated with 
trypsin, at ~4S and ~3.6S) , and has a molecular weight of 
70,000 daltons; the nuclear estrogen receptor sediments at 
~5S (124, 142). They have equal densities, and roughly 
equal DNA-binding abilities and molecular weights (6). 
Unbound receptor of either type is susceptible to photoox¬ 
idation (59) , 
Type I binding sites are classically high-affinity, 
easily saturable binding sites, while type II sites are of 
lower affinity, but have a higher capacity for estradiol. 
It is very possible that they represent extracellular 
binding proteins. 
Dickerman's model contained two binding domains: a 
steroid binding domain with an estradiol binding site; and a 
polynucleotide binding domain with a deoxyguanylate binding 
site (dC = dT>dA) , and a histone binding site (Fig 8) . 
Dickerman notes that the deoxyguanylate binding site 
corresponded to the deoxynucleotide with the greatest 
binding affinity, but that oligo (dT) and oligo (dC) follow 
oligo (dG) by a close margin in their respective binding 
affinities (51) . 
Importantly, his model does not specifically consider 
the role of RNA discussed earlier, namely one of negative 
feedback inhibition, a role which has become increasingly 
probable. Benz et al have proposed such a model (Fig 9), 
which considers all the data presently available (114). It 
. 
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provides for estradiol diffusing through the cell membrane, 
binding to cytosolic ER, and activation of the ER-E2 complex 
(dependent upon temperature, ionic strength, unknown 
factors). After diffusing through the nuclear membrane, the 
activated ER-E2 complex binds to nuclear chromatin, with 
specific binding sites containing poly (G,T) sites (cf. 51). 
RNA transcription can then take place. Products of RNA 
breakdown have specific sequences with an affinity for poly 
(U,G) (cf.101), probably based on ionic or electrostatic 
rather than covalent forces (131, 127). 
This model will ultimately prove very useful in 
incorporating the data presented in this thesis into a 
unified theory accounting for tamoxifen-fluorouracil 
synergy. 

CHAPTER X 
MATERIALS AND METHODS 
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CELL LINES 
The breast cancer cell line MCF-7 is a 
well-characterized, continuously growing monolayer cell line 
with a doubling time of 35 hr. It was grown in RPMI 1640 
media (obtained from Gibco Labortories, Grand Island 
Biological Co., N.Y.). Unless otherwise indicated, it was 
supplemented with insulin (0.2 IU/ml), estradiol (InM) and 
fetal calf serum (10%; Gibco). Stock cultures were grown in 
75 cm.2 and 150 cm2 sterile plastic culture flasks (Costar 
Data Packaging, Cambridge, MA) with 25 ml and 50 ml, 
respectively, of supplemented media. They were incubated in 
5% C02 incubators at 37 degrees C. Single cell suspensions 
were prepared from cultures using a trypsin (0.05%) - EDTA 
(0.02%) solution. Cell counts were performed on a model ZBI 
Coulter Counter (Coulter Electronics, Inc., Highleah, FL) . 
When indicated, cells were grown with a 1:1 mixture of fetal 
and neonatal calf serum, dialyzed fetal calf serum (Gibco), 
as media not supplemented with estradiol. The estradiol 
content of undialyzed commercial serum was measured by 
radioimmunoassay to be < 100 pM. Therefore, cultures not 
supplemented with estradiol contain < 1% of the estradiol of 
stock cultures. Where indicated, cells were grown in serum 
stripped of endogenous estradiol by dextran coated charcoal 
adsorption. All drugs were purchased from Sigma (St. Louis, 
MO) except tamoxifen citrate (Stuart Pharmaceuticals, 
Wilmington, DE) . Flasks were seeded with 4 million cells 
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48-72 hours before adding drugs in order to obtain cells in 
logarithmic phase. Drugs were rinsed off the monolayer 
colonies with phosphate-buffered saline (PBS) and fresh 
media was added. 
RNA FRACTIONATION AND ANALYSIS 
Sucrose gradient centrifugation was performed on RNA 
extracted from whole cells using the procedure of Lizardi 
(107). This technique is capable of resolving 4S, 8S, 28S 
and 45S RNA. RNA from labeled cells was layered onto 5-47% 
linear sucrose gradients and run for 18 hours at 26,000 rpm 
in an SW27 rotor at 4 degrees. The 0.6 ml fractions were 
collected and run through a UV monitor directly into 
scintillation vials, into which 1.4 ml of water and 10 ml of 
scintillation fluid (Aquasol, New England Nuclear, Boston, 
Mass.) was placed before counting on a Packard Tricarb 
scintillation counter. 
RECEPTOR BINDING TO DNA-CELLULOSE 
Purified estrogen receptor of cells treated with 
5-fluorouracil, tamoxifen or control cells, as noted 
(isolated as described below), was assayed for its effects 
binding to DNA cellulose by the modifications of the methods 
of Hollander et al (88, 61) and Liao et al (101). Combined 
cytosol and nuclear extracted (3H)ER was prepared in 
connection with receptor studies described below. 
DNA-cellulose (400 g/ml) was prepared by the drying 
procedure of Alberts and Herrick (1) using calf thymus DNA 
(P-L Biochemicals) and Cellex grade cellulose Bio-Rad 
■ 
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Laboratories, Richmond, CA). Cellulose treated without DNA 
was used as a control. 
Where indicated, the Liao DNA cellulose column assay 
was used (101). DNA-cellulose (0.5 mg), prepared as 
indicated above, was packed into a glass column (this was 
0.5 mg DNA/column) and washed with Medium ET (20 mM 
Tris-HCl, pH 7.5, 1.5mM EDTA) with 0.1 M KC1 was added to 
the column (this was ~ 10,000 cpm) and incubated at 20 
degrees C for 30 minutes. Columns were washed seven times 
with 0.5 ml Medium ET with 0.1 M KC1 in order to remove free 
steroid or steroid-receptor complex which did not bind to 
DNA-cellulose. The steroid-receptor complex that remained 
attached to DNA-cellulose was eluted with 0.5 ml Medium ET 
with 0.6 M KC1 and counted in 2 ml Liquiscint 
(toluene-based) scintillation cocktail. 
Where indicated, the Liao DNA-Cellulose Centrifugation 
Assay was used (101) . 
Into large microfuge tubes, 20-100 ul of DNA-cellulose 
(this makes 20 to 100 mg DNA) and the radioactive complex 
(usually 2,000-10,000 cpm) along with 0.5 ml Medium ET were 
placed. Where indicated, a test compound was added to the 
microfuge tube at this stage. The contents were mixed and 
incubated at 20 degrees C for 5 minutes, then spun for 5 
minutes in a Beckman microfuge. The DNA-cellulose pellet 
was washed 5 times with 1.0 ml Medium ET with 0.1 M KC1. 
The entire contents of the microfuge tubes were placed into 
scintillation vials with 2.0 ml toluene-based scintillation 
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cocktail. Quench was found to be within 1% in both control 
and drug-treated groups. 
ESTROGEN RECEPTOR ISOLATION AND EXTRACTION 
MCF-7 cells were taken from storage at - 70 degrees C 
after having been harvested as described previously. (61) . 
To the partially thawed pellet of cells was added 1.0-1.5 
volumes of Buffer A (lOmM Tris, pH 7.4, 1 mM EDTA, 1 mM 
dithiothreitol, prepared < 4 hours before use) at 0 degrees 
C. Keeping on an ice bath at 0-4 degrees C, the cell pellet 
was sonicated at 250 W for two 10-second bursts, the minimum 
sonication to obtain more than 90% cell lysis (verified with 
light microscopy using a trypan blue stain) . Benz et al 
have determined that sonication performed in this manner 
does not have significant effect upon estradiol to receptor 
(13). The mixture was incubated for 60 minutes at 0-4 
degrees C with intermittent (every 15 minutes) vortexing. 
The mixture was spun at 2800 RPM for 20 min in Beckman 
Centrifuge. The pellet was discarded and the supernatant 
was washed twice with 2.0 ml of PBS containing 1% Tween 80; 
this improved the ratio of specific to nonspecific binding. 
The supernatant was incubated at 0-4 degrees C in 10 nM 
(3H) E2 +/- 100-fold excess DES for 5 hours to determine 
nonspecific binding. DES is used because, unlike unlabeled 
estradiol which could theoretically also be used, DES has a 
very low affinity for alpha-fetoprotein (12) , a source of 
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spurious specific binding. A 42.8% volume of chilled (0-4 
degrees C) saturated (NH4)2 S04 was added and incubated at 
0-4 degrees C for 30 minutes with intermittent mixing (each 
thirty minutes). 
Where indicated, a protamine sulfate precipitation was 
performed after a modification of the method of Horwitz et 
al (71) . The mixture was spun at 2800 RPM for 20 minutes 
and the supernatant discarded. The pellet was resuspended 
in 1.0 ml Buffer A + 0.1 M KC1 and mixed thoroughly by 
vortexing, standard Sephadex LH-20 columns were prepared 
(126) . These were used to separate macromolecular bound 
from free radioactivity. Two 100 ml samples were taken and 
assayed for protein content by the Bradford protein assay 
(30) (obtained from Bio-Rad Laboratories) . Samples were 
vortexed and placed in a toluene-based scintillation 
cocktail for measurement of radioactivity. 

CHAPTER XI 
RESULTS 
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DEVELOPMENT OF ASSAY 
The methods described in "Materials and Methods" were 
used to culture MCF-7 human breast cancer cells. It was 
important to have adequate amounts of estrogen receptor in 
order to perform very accurate specific binding estrogen 
receptor assays, and to use the same estrogen receptor for 
DNA-cellulose binding assays. 
Cells were compared with respect to the amount of 
specific binding (and hence level of estrogen receptor) in 
control MCF-7 cells, MCF-7 cells raised exclusively in 
Gelding serum (which contained < 3 fmol/mg protein estrogen 
receptor — undetectable levels), and MCF-7 cells raised in 
dextran coated charcoal-stripped 10% fetal calf serum (see 
"Materials and Methods"). 
Geldina DCC Control 
Specific E2 binding 
Lela.tl.ye to. .control .-.ifl--l.9jj . 97rl.05.% 10fll 
Two seperate experiments were carried out, with the 
results shown. Quantitatively, the amount of estrogen 
receptor was compared in MCF-7 cells raised in dextran 
coated charcoal-stripped serum with MCF-7 cells raised in 
gelding serum. In two seperate experiments, Dcc-stripped 
serum cells had 3.63-7.26 times as much specific binding 
(mean 5.4, SD 2.56) (expressed as fmol/mg protein bound). 
This range may be accounted for by the variability in 
estradiol content of Dcc-stripped serum. 
. 
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Next, Dcc-stripped serum MCF-7 ER and ER from control 
MCF-7 cells were compared (isolated as indicated in 
"Material and Methods"). There was no difference is 
specific binding of the two groups in two separate trials. 
We attempted to determine if estrogen receptor was heat 
labile. Experiments in control MCF-7 cells were carried out 
at 0 degrees C and at 17 degrees C. There was no detectable 
specific binding in cells in which the incubation step was 
performed at 17 degrees C, while experiments conducted at 0 
degrees C showed expected levels of specific binding. 
Two different assays for specific binding of (3H) 
estradiol were compared with respect to their levels of 
specific binding, the amount of protein (determined by 
Bradford assay) and the ability of the estrogen receptor to 
be applied to a DNA-cellulose column (a step necessitating 
resolubilization of the estrogen receptor fraction). The 
methods were the protamine sulfate precipitation assay of 
Chamness et al (14) and the ammonium sulfate precipitation 
reaction of Feldman et al (56) . 
Protamine sulfate and ammonium sulfate precipitation 
experiments produced identical levels of specific binding of 
(3H)E2 to ER, and similar amounts of protein, making them 
equally good assays for assessing fmol (3H)E2 bound per mg 
protein. However, the protamine sulfate precipitate showed 
poor resolubilization characteristics in heparin, making it 
difficult to apply samples to the very sensitive Liao 
DNA-cellulose column. As a result, the 40% ammonium sulfate 
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precipitation reaction was employed for DNA-cellulose 
studies. 
The levels of specific binding were compared when the 
precipitation step of the estrogen binding assay was 
performed before and after the incubation step with (3H)E2 
+/- excess DES. The yields were significantly higher when 
the precipitation step was conducted after the incubation 
step (data not shown). 
The limits of resolution of the ammonium sulfate 
precipitation assay were explored. It was found that 
specific binding was detectable at 1/20 of standard sample 
sizes of labeled estrogen receptor fraction described in 
"Materials and Method." 
3Urd INCORPORATION INTO RNA 
Sucrose gradient centrifugation was performed on the 
MCF-7 RNA fraction (isolated according to "Materials and 
Methods") in control cells treated with 3Urd (Figure 17) , 6 
hours of 5uM 5-FU (Figure 18) and 5uM 5-FU after 
pretreatment with 72 hours TAM (Figure 19). 
Standard RNA samples of 4S, 18S and 28S were applied to 
a sucrose gradient in order to determine standard RNA peaks. 
The fractions on the X-axis represent groups into which the 
indicated RNA species fall, and not fraction number. 
There was an increase in incorporation of 3Urd over 
controls (3Urd was used in all gradients except the RNA 
■ 
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standards) into the 32-45S RNA segment in both the 5-FU 
treated and the TAM-pretreated, 5-FU treated MCF-7 cells. 
There was less (85% of controls) incorporation of 3Urd into 
the 18-28S RNA segment in the 5-FU treated cells, and 
markedly less (38% of controls) 3Urd incorporation into the 
18-28s RNA segment in the case of the TAM-pretreated, 5-FU 
treated cells, compared with control MCF-7 cells. 
Similarly, the incorporation of 3Urd into the <4S 
segment was less (74% of controls) in 5-FU treated cells, 
and much less (26% of controls) in TAM-pretreated, 5-FU 
treated cells. The area under the curves was calculated for 
each subsection. 
The significance of these observations is discussed in 
"Discussion Section." 
ER - (3H)E2 BINDING 
In three separate trials, specific binding of estrogen 
receptor to (3H)E2 was examined. MCF-7 cells were treated 
with a 6 hour exposure to 5uM 5-f luorouracil. Specific 
binding was increased in each case, whether it was expressed 
as fmol (3H)E2 bound per million cells (mean 1 60% of 
controls, SD 42.1%) or fmol (3H)E2 bound per mg protein 
(195% of controls, SD 60.7%) by Bradford assay). The 
methods used are described in "Materials and Methods." 
figure 21 for results. 
See 
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RECEPTOR-DNA-CELLULOSE BINDING 
Modifications of the Liao centrifugation and column 
assays (see "Materials and Methods") were used to assess the 
effect of 6 hours of 5uM 5-FU pretreatment in MCF-7 cells on 
estrogen receptor binding to DNA-cellulose. The results are 
presented in Table 16. The centrifugation and column assays 
were compared with respect to their ability to detect 
whether or not 1200 cpm of (3H) estradiol-receptor complex 
applied to the column bound to DNA-cellulose. It was found 
that detectable binding of receptor to DNA-cellulose 
resulted only in the centrifugation assay at this low level 
of radioactivity. 
In two trials, 5uM 5-FU pretreatment for 6 hours 
increased binding of MCF-7 estrogen receptor to 
DNA-cellulose. Methods of calculating binding are described 
in the legend of Figure 16. The significance of these 
results is discussed under "Discussion Section." 
■ 
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TAMOXIFEN - 5-FLUOROURACIL SYNERGY 
A number of studies have shown significant clinical as 
in vitro benefits from combined chemo- and endocrine therapy 
involving tamoxifen. 
Mouridsen's group found a significant benefit in 
combining CMF (cyclophosphamide, methotrexate, 
5-fluorouracil) with tamoxifen, increasing the response rate 
(partial or complete remission) from 45% to 70% (115) in 
postmenopausal women with advanced breast cancer. A recent 
series in the New England Journal of Medicine summarized the 
results of the NSABP (National Surgical Adjuvant Breast and 
Bowel Project) : when tamoxifen was added to a regimen of 
C-phenylalanine mustard combined with 5-fluorouracil, there 
was a suggestion of benefit in women over 50 years old with 
low levels of estrogen receptor (61). 
One study in particular, by Allegra1s group at the 
University of Louisville, demonstrates the necessity of 
attempting to establish a chemotherapeutic regimen based 
upon rational rather than empiric principles: Allegra1s 
group found, in a Phase II clinical trial with a protocol of 
TAM, premarin, methotrexate and 5-FU, that the response rate 
in patients with advanced breast cancer was fully 72%, with 
a complete remission rate of 56%, all with minimal systemic 
toxicity. While his sample size was small (25 patients) , 
these results are extremely encouraging; the usual complete 
remission rate is less than 10-15% (147). 
Allegra attributes his apparent success to the broad 
. 
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coverage of TAM and 5-FU of slow-growing, ER containing, as 
well as rapidly-growing, ER-negative tumors, respectively. 
Significantly, his patients did not have dominant visceral 
metastases, in contrast to patients of other investigators. 
Furthermore, he believes that his chemotherapeutic regimen, 
allows for the methotrexate pretreatment to synchronize 
cells, releasing them when thymidine incorporation, and 
hence DNA synthesis, is at its maximum, and therefore most 
vulnerable to chemotherapy (3). 
This explanation is not completely satisfactory, since 
RNA synthesis, which is cell-cycle constitutive (except for 
the mitotic phase), accounts more for the toxicity of 5-FU 
than do the DNA-directed effects, as we have seen. 
In spite of these very encouraging studies, a number of 
investigators have demonstrated equivocal (123, 36) or even 
antagonistic (120) results in combined chemo-endocrine 
therapy. In vitro, a number of studies have shown that 
tamoxifen pretreated breast cancer cells are synergistically 
cytotoxic with 5-FU treatment (Figure 10). For the MCF-7, 
the expected percent clonal growth of cells exposed to 5uM 
5-FU for 6 hours, 12 hours before harvesting is 91%. For 
the same cells exposed to lOuM tamoxifen alone continuously, 
the percent clonal growth is 21%. If both drugs acted 
independently of each other, and none of the effects were 
overlapping (i.e. if none of the 9% killed by 5-FU were the 
same as the 79% killed by TAM) , the expected combined 
cytotoxicity would be (.91) (.21) = .19, or 19%. The actual 
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observed cytotoxicity is 6%, less than third of that 
predicted; the 0/E ratio, or ratio of observed cytotoxity to 
expected cytotoxity, is .31. Similar experiments under 
identical drug conditions in the 47-DN human breast cancer 
cell line concur (21). Here, the results were 93% clonal 
growth with 5-FU treatments 58% clonal growth with TAM, 26% 
with TAM and 5-FU, for an 0/E ratio of .48, indicating 
synergy. 
Clearly, these drugs are not acting independently. It 
is very tempting, and potentially of extreme clinical 
usefulness, to explain this drug synergy on the basis of 
cellular and biochemical phenomena, much as Cadman's group 
explained, thus far unassailably, the synergy between 
methotrexate and 5-FU on the basis of an increase in 
intracellular 5-phosphoribosyl-l-pyrophosphate pools induced 
by the dihydrofolate reductase inhibition of methotrexate, 
and a resultant increase in conversion of 5-FU to its toxic 
metabolites (34). 
It is conceivable that cells that are weakened by one 
form of therapy (and therefore not be evident in cells 
killed) would be killed if another damaging but non-lethal 
drug were applied. Young's group, for example has made the 
observation that lymphocytes resistant to the effects of 
glucocorticoids succomb to them if maximally weakened with 
other, non-lethal agents (160). While this theory is 
possible, the method of measuring clonal growth assesses 
maximally weakened, and therefore probably non-dividing 
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cells, as contributing to overall reduction in clonal cell 
growth (when extrapolated to a significant subpopulation of 
cells). 
We have examined the effects of 5-FU on RNA processing 
and protein synthesis. It is likely these RNA-directed 
effects play a role in explaining TAM-5-FU synergy. 
Benz et al have found that TAM pretreatment of MCF-7 
cells resulted — surprisingly, if one considers the synergy 
— in an overall reduction in intracellular accumulation of 
5-FU; moreover, total incorporation of its metabolites was 
decreased from 20-60% (23). 
In spite of an overall net reduction of intracellular 
5-fluorouracil accumulation, tamoxifen enhances its 
toxicity; in this sense, it is unique. 
Nor does it seem that TAM-5-FU synergy is mediated by 
synchronization alone (19), since some synergy is observed 
at a wide variation of doses and exposure times. Moreover, 
tamoxifen synchronization of cells subsequently treated with 
5-fluourouracil did not appreciably alter fluorouracil 
toxicity (19). 
It seems likely that 5-FU toxicity is mediated 
primarily through incorporation into RNA. It has been shown 
that while overall intracellular accumulation of 
5-fluorouracil into cells is decreased by 20-60%, and total 
RNA decreased by 10-20%, cells treated with tamoxifen alone 
contained 10-20% less cellular RNA and exhibited altered RNA 
turnover — independent of treatment with 5-fluorouracil. 

77 
Sucrose gradient centrifugation of newly synthesized 
RNA reveals more specifically how TAM and 5-FU affect RNA 
processing. The specific incorporation of a 6 hour exposure 
to 5-FU was compared with a 2 hour exposure to FUrd and 
radiolabeled uridine as a control. In one particular 
segment in cells pretreated with 5-FU namely the 32-45S 
segment, incorporation increased nearly two-fold. More 
significantly still, when the 5-fluorouracil metabolite 
5-fluorouridine (FUrd) was used (whose effects are 
predominantly due to FUTP incorporation into RNA) 
incorporation into the 32-45S is increased almost three-fold 
(23) (Figures 7, 11) . 
Accumulation into this high molecular weight segment of 
RNA is most directly correlated with an inhibition of rRNA 
processing. There is a significant amount of data 
suggesting that low molecular weight species exert the 
maximal inhibitory binding between estrogen receptor and 
DNA-cellulose. Feldman et al (61) found that 16S and 23S 
species of RNA were most inhibitory; however, they did not 
specifically test the 32-45S segment, nor did they test 5-FU 
treated RNA (problems addressed in this thesis). 
The results presented under the "3Urd Incorporation 
into RNA" Section of this thesis demonstrate increased 
incorporation of 3Urd into 32-45S RNA, a finding consistent 
with preliminary data from Benz and Cadman (23). 
The results presented indicate that at low, growth- 
inhibiting doses of 5-fluorouracil, binding of (3H) 
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estradiol to estrogen receptor is markedly increased over 
controls. This would imply that the binding of TAM, acting 
through the estrogen receptor, would also be increased, 
resulting in more TAM-ER complex to bind to nuclear 
chromatin. 
This finding has found support from several other 
techniques (Figure 20), among them the cytosol protein 
extract assay of Horwitz (74), the Shafie and Brooks whole 
cell assay (141) and flow cytometric data using Raber's 
methods (127) , all of which revealed increased binding of 
5-FU (at a minimally toxic concentration)-treated MCF-7 ER 
to (3H) estradiol. 
However, Benz and coworkers have also found that (3H) 
estradiol binding to ER actually decreases when more toxic 
doses of 5-FU are used (14) , consistent with the preliminary 
finding of other investigators (i.e. Yang and coworkers) 
(158) , that a dose-dependent reduction in binding of (3H) 
estradiol to ER is found in the MCF-7 cell line with 
increasing doses of cytotoxic drugs (i.e. 5-FU) (Figure 15). 
Yang's group utilized the whole cell assay of Shafie and 
Brooks. These apparently conflicting results may be 
explained by different effects on intracellular metabolism 
and ER function between toxic and non-toxic doses of 5-FU. 
It is also possible that MCF-7 strains differ in the nature 
of their estrogen receptors (cf. Horwitz findings of two 
completely different MCF-7 strains) (71) . All things 
considered, it is very likely that increased ER binding of 
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(3H) estradiol is not a major mechanism in TAM-5-FU synergy. 
Interestingly, the Scatchard analysis of the binding 
data (Figure 15) reveals that after treatment with toxic 
concentrations of 5-FU, receptor number is reduced, while 
affinity of (3H) estradiol for receptor is unchanged. This 
indicates that cytotoxic drugs may cause a reduction in the 
amount, but not in the quality, of ER, consistent with the 
finding of decreased protein synthesis in 5-FU treated MCF-7 
cells (53) . 
It is known that TAM, along with other antiestrogens, 
must bind to nuclear chromatin before exerting its cytotoxic 
effects (7) . According to the estrogen receptor model by 
Benz et al, RNA — particularly of the sequence poly (U,G) 
— feeds back on the estrogen receptor, preventing its 
binding (and therefore its initiation of transcription) to 
nuclear chromatin. Any factor promoting TAM binding to 
nuclear chromatin would effectively increase the 
"intranuclear dose" of TAM, resulting in reduced RNA, DNA, 
protein synthesis. 
By inhibiting RNA processing, 5-FU may be performing 
this function, and if the RNA recognition site on the 
estrogen receptor is specific, as several studies have 
suggested (i.e. 61, 101, 40), the 5-FU-induced change could 
conceivably be a small structural one, with a large 
resultant decrease in RNA binding to receptor. This is very 
likely, especially considering the wide variability of 
binding of different nucleotides and polynucleotides to 
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DNA-cellulose exhibited in these studies (esp. 108) . One can 
conclude that this step augmenting TAM's effects on 
chromatin is qualitatively more important than the 
dose-dependent reduction in (3H)E2 specific binding after 
administration of cytotoxic drugs reported by Yang's group 
(158r)r and independently by Benz et al (114). 
In both of the latter cases, no qualitative difference 
in the ER was noted after treatment with 5-FU: in both 
cases Scatchard analysis showed no change in the affinity of 
the receptor for its ligand —- (3H)E2 — but a reduction by 
25-64% of ER levels at varying concentrations (160) , and 50% 
reduction in ER at a single concentration. 
It is therefore more important how much TAM-ER binds to 
template, and less important how much free cytosolic ER is 
present. 
This finding is substantiated by preliminary findings 
that not all tumors which contain ER respond to TAM: in a 
malignant melanoma cell line, for example, ER has been found 
which exhibits normal Scatchard behavior for specific 
binding, i.e. ER is present? however, TAM has no effect upon 
the cell line. Another finding which elucidates the matter 
is that no transfer of receptor-ligand to the nucleus 
occurs, similar to the situation in liver cells, where 
glucocorticoid receptors are present (as in lymphocytes) but 
hepatocytes do not respond to glucocorticoid administration, 
while lymphocytes do. Again, there is no translocation of 
receptor-hormone complex to the nucleus. 
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Preliminary data presented here (Figure 16) suggest 
that pretreatment of MCF-7 breast cancer cells with 5-FU 
(5uM for 6 hours) results in increased binding of (3H)ER to 
DNA cellulose, an in vitro correlate of nuclear template. 
The estrogen receptor was isolated using a modification 
of the Feldman, Kallos, Hollander (NH4)2 S04 precipitation 
(61). ER from control cells were compared with respect to 
their ability to bind to DNA-cellulose by modifications of 
two techniques described by Liao et al (101): the column 
method and the centrifugation method. In both cases, 
cellulose without DNA was used as a control. As a second 
control, it was necessary to substitute a 100-fold excess of 
DES in order to obtain specific binding. Table 15 indicates 
that the centrifugation method may be the more sensitive 
assay: at a lower overall amount of radioactivity (1200 
cpm) 52 cpm of specific binding in cells treated with 5uM 
5-FU were detected, compared to 0 cpm for control cells not 
treated with 5-FU. This compares with only 17 specific cpm 
in the 5uM 5-FU treated MCF-7 cells in the column assay. 
The centrifugation assay of Liao appeared to be quite 
specific. When greater concentrations of control (i.e. not 
treated with 5-FU) MCF-7 ER were applied, at cpm levels of 
3600 and 8000 cpm, no nonspecific binding was detected, 
while with the column assay 113 nonspecific counts were 
detected when 3600 cpm were applied to the column. 
These data suggest that 5-FU pretreatment of MCF-7 
cells results in greater binding of the resultant ER to 
;-C*5 
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nuclear template. It is known that certain RNA species 
inhibit binding of ER to DNA-cellulose, and that 5-FU 
impairs RNA processing. 
It is entirely consistent with the ER model of Benz et 
al that inhibiting RNA processing would increase binding of 
ER to DNA-cellulose, and therefore also of TAM to 
DNA-cellulose, since evidence suggests TAM acts through the 
estrogen receptor. Pretreatment with 5-FU may effectively 
diminish the negative feedback loop at the RNA-receptor 
level. 
This is an attractive hypothesis for several reasons, 
and is supported by three lines of evidence presented in 
this thesis: 5-fluorouracil, and to a lesser extent 
probably also tamoxifen, impair RNA processing; 
5-fluorouracil by increased incorporation into 32-45S 
segment of RNA (Figures 18, 19), tamoxifen by other, less 
well-defined mechanisms. The binding of activated receptor 
to DNA-cellulose appears also to be increased, a necessary 
progression from the first data. Tamoxifen binding to 
nuclear template, the site of its presumed cytotoxic 
mechanism, is therefore also increased. The increased 
binding of receptor to (3H) estradiol (and therefore, 
according to our model, also to tamoxifen), is relegated to 
secondary importance, since its presence or absence has no 
affect on the ultimate TAM-5-FU synergy observed in vitro. 
Drawing the latter two conclusions would have been 
impossible without a very specific assay in which estrogen 
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receptor levels could first be quantitated, then applied to 
the second DNA-cellulose assay. 

CHAPTER XIII 
CONCLUSION 
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The study of the TAM-5-FU question is far from finished, 
since there are numerous studies that would clarify matters 
further. It is tempting, for example, to conduct ER 
specific binding assays with radioactive TAM, or better yet 
radioactive OH-TAM, which has a lower Kd than its 
nonhydroxylated relative, and follow through with 
DNA-cellulose binding studies. This would dispel any doubt 
of TAM's actions being mediated through a separate receptor. 
Are the actions of other antiestrogens than TAM mediated 
through other receptors? What is their optimal scheduling; 
or how can we maximize total synergy by maximizing each 
contributing component? 
Since drugs such as 5-FU and TAM have such clear in 
vitro and clinical merit in treating breast cancer, and are 
so readily at hand, it would be a mistake not to explore 
methods to maximize their utility. 
Ultimately, definitive treatment may come from other, 
not yet well-defined approaches. It may be possible to 
inhibit estrogen biosynthesis via aromatase inhibitors 
(Brodie, 31), to prevent new cellular growth by inhibiting 
prostaglandin synthesis specifically (Bennett, 8), by 
actually structuring a molecule consisting of an estrogen 
combined chemically to an antimetabolite (Leclerq, 99) , or 
by using pituitary or hypothalamic releasing hormones to 
inhibit steroidogensis (Corbin, 49), among many, many 
others. 
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Our goal must be individualized treatment of cancer- 
based on its receptor types, histological characteristics, 
growth characteristics and the patient's expectations of 
treatment. 
It is not unreasonable to think that we have arrived in 
the era when pharmacology can be based upon molecules 
individually built for each disease, much in the same 
fashion as the angiotensin converting enzyme inhibitor 
antihypertensives were designed to minimize side effects and 
maximize enzyme inhibiting capabilities. It was first 
necessary to characterize receptor sites and functional 
groups in exquisite, three dimensional detail. 
If this seems whimsical in the case at hand, TAM-5-FU 
synergy, witness the large body of recent data, each study 
suggesting a single aspect of estrogen receptor structure 
and function; our understanding of the current model is a 
vast and welcome improvement over the models extant even 5 
years ago, and exciting questions continue to suggest 
themselves, as we draw inexorably nearer to optimization of 
our current regimens. 

CHAPTER XIV 
FIGURES 

de novo Pyrimidine de novo Purine 
Figure 1. Proposed interaction of MTX and FUra. Broken arrows, 
multiple enzymatic steps. Enzymes (circled numbers): 1, 
amidophosphoribosyltransferase; 2, phosphoribosyl gly- 
cineamide formyltransferase; 3, phosphoribosyl aminoimi- 
dazole carboximide formyltransferase; 4, thymidylate syn¬ 
thetase; 5, dihydrofolate reductase; 6, orotate phospho- 
ribosyltransferase; and 7, phosphoribosyl pyrophosphate 
synthetase. MTX inhibits Enzyme 5, and dTMP synthesis 
contimues until the tetrahydrofolate pools no longer 
support the methyl transfer to dUMP. Because of this re¬ 
duction in tetrahydrofolate pools, purine synthesis is 
also inhibited. 5-fluorodeoxyuridine monophosphate di¬ 
rectly inhibits Enzyme 4 in the presence of tetrahydro¬ 
folate. FUDP, 5-fluorouridine diphosphate: FdUMP, 5- 
fluorodeoxyuridine monophosphate; FUTP, 5-fluorouridine 
triphosphate; OMP orotidine monophosphate; FH4, tetra¬ 
hydrofolate; FH2, didydrofolate. Reproduced with per¬ 
mission from Cadman et al (25). 
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Acetate Cholesterol 
I 
I 
Pregnenolone OH 
2ICH3 
Figure 2. Synthesis of estradiol from cholesterol, showing 
related compounds, including diethystilbestrol (DES). 
Adapted from Goodman and Gilman (62). 
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Clomiphene 
Figure 3. Three commonly used antiestrogens. From Goodman 
and Gilman (62). 
o 
H 
Fluorourocil 
IP*, 8 1) 
Figure 4. 5-Fluorouracil (5-FU) and Methotrexate 
From Goodman and Gilman (62). 
(MTX). 
■ 
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Figure 5. The Cell Cycle. From Gray's Anatomy (156). 
that protein synthesis and RNA synthesis are const 
DNA synthesis is not. 
ANTIESTROGEN ACTION 
responses 
I, 2,3,4,5. 
only some 
responses 
1,2... 
Figure 6. Model of Antiestrogen Action. E-estrogen AE 
From Katzene1lenbogen et al (82). 
Note 
tutive, 
antiestrogen. 
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A [ jh] Urd ( M. 6hr) 
50 r 
B [JH]FUfO <5MM, 6hr> 
50 r 
RNA Fractions 
32-45s 
32-45s 
Figure 7. Percentage of distribution of (3H) uridine (Urd) and 
(3H) FUra incorporation into grouped fractions of 47-DN. 
Results from sucrose gradient centrifugation assay. From 
Cadman et al (19). Note greatly increased incorporation 
into 32-45S fraction upon (3H) FUra treatment. 
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^ "De©*ynvcleotide binding site (dCsdT>dA) 
H = Nucleosomol histone-reoctive site 
Figure 8. The Dickerman Estrogen Receptor Model. From 
Dickerman et al (51). 
Figure 9. An Autoregulated Estrogen Receptor Model. From 
Miller and Benz (114). 
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T47-P 
A. 
& 
Figure 10. Unpublished data showing dose-dependent reduction 
incorporation of (3H) dGuo into DNA in T-47-D human 
mammary carcinoma cell line. From C. Benz (114). 
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B. 
Figure 11. RNA fractionation on sucrose gradients showing 
increased incorporation of (3H) 5-FU into 32-45S seg¬ 
ment of RNA in MCF-7 human breast cancer cell line. 
S. Control 
B. After 5uM 5-FU x 6 hr. From Benz et al (114). 

Mean X Clonal Growth 
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Cell Line FUra (SuM, 6hr) TAM (lOtiM)* TAM-FUra 0/E" 
MCF-7 91X 21X 65 .31 
47-ON 93X sex 26X .48 
•TAM administered continuously to MCf-7 and for 72 hr to *7-GM. 
"observed/Expected (0/E) clonal growth: < 1.0 * .2 * synergism. 
» 1.0 • antagonism 
Figure 12. Tamoxifen (TAM) and 5-fluorouraci1 (5-FU) exhibit 
synergistic cytoxicity in two human breast cancer cell 
lines. Note that O/E ratios of less than 1.0 indicate 
synergy. From Benz, Moelleken, Benz, Wiznitzer (21). 
Colo-3S7 Clonal Growth 
Control 
TAM 
(lOuM) ^2 (SuM) Pg (2.SuM) (*") 
uM FUra 0 100X 86 X ssx 44X ex 
IS 91X 61X 25X ex IX 
20 795 43X 26X 7S <1X 
0/E* .785 .32 .2 .1 
.63 39 .2 «.i 
•Observed/expected (0/E) clonal growth: <1.0 t .2 ■ synergism, >1.0 ■ antagonism 
Figure 13. In COLO-357 human pancreatic carcinoma cell line 
TAM is synergistic with estradiol (E2) or progesterone 
(Pg), From Benz, Moelleken, Benz, Wiznitzer (21). 
Cell Line I025 TAM specific E2 binding* 
MCF-7 0.1 ftM 
47-0M 2uM 1 nM 
Colo-357 KXiM 5 nM 
•Dissociation constant by Seatchard analysis of whole cell 
ER assay using 0.2 - 3.0 nH [3h]-E7 ♦ 100 fold excess OES 
at 37*C * 1 hr. 4 
Figure 14. Sensitivity to TAM (as indicated by concentration 
of tamoxifen necessary to inhibit clonal growth by 25%) 
parallels receptor affinity for estradiol. From Benz, 
Moelleken, Benz, Wiznitzer (21). 
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Figure 15. Fluorouracil decreases total specific binding to 
estrogen receptor. However this is not mediated by a 
change in receptor (see 8 Scatchard plots above) but 
by a reduction in the number of estrogen receptors. 
Data from T47-D human breast cancer cells. From Miller 
and Benz (114). 
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Group Specific cpm 
applied in 
assay 
Centrifugation 
Method 
Column 
Method 
Control 1200 none detected none 
detected 
5uM 5-FU 
(6 hr.) 
1200 52 none 
detected 
Control 2000 none 
detected 
5uM 5-FU 
(6 hr.) 2000 17 
Control 3600 none detected 113 
Control 8000 none detected 
Figure 16. Specific Binding of (SlQE^ to DNA-Cellulose. Calculations 
were determined by (cpm of DNA-cellulose - cpm of control cellu¬ 
lose) - (cpm DNA-cellulose plus lOOxs DES - cpm control cellulose 
with 100 xs DES). 
"Specific cpm" denotes cpm of (3H) E^ - receptor complexes 
applied to the column. "None detected" indicates that no binding 
of this complex to DNA-cellulose was observed. 
Note that when 1200 "specific cpm" are applied to the column, 
binding to DNA-cellulose (52 cpm) is observed only in the centri¬ 
fugation method, indicating that it is the more sensitive assay. 
Notable also is that both at very low levels of radiation 
applied to the centrifugation method (1200 cpm) and at medium 
levels applied to the column method (2000 cpm), detectable binding 
resulted only in the 5uM 5-FU treated cells, leading to the pre¬ 
liminary conclusion; 5-FU increases binding of (SlQE^ complex to 
DNA-cellulose. 
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Figure 17. Sucrose gradient centrifugation of control 
MCF-7 cells. Note peaks at < 4S RNA and 18-28S 
RNA, and no significant incorporation of 3Urd in¬ 
to 32-45S segment. 
; 
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Figure 18. Sucrose gradi 
treated MCF-7 cells, 
and increased 32-45S 
ent centrifugation of 5uM (3H) 5-Fu 
Note decreased <4S, 18-28S Peaks, 
peak over control (cf. Figure 17). 
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Figure 19. Sucrose gradient centrifugation of TAM-pretreated, 
(3H) 5-FU treated MCF-7 cells. Note very little ^ 4S, 
18-28S; and increased 32-45S peaks compared with control 
(cr. Figure 17). 

Specific Estradiol Binding 
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Control(fnol/mg oroteln) 
(method A) 
5u*1 FUn 
(Method B) 
x 6 hr (X control) 
(Method C) (Method 0) 
MCF-7 44.0 1741 155X 
47-DN 22.0 133X 
Colo-357 19.5 
- 156% 
Figure 20. Several lines of evidence suggest spcific estradiol 
binding increases after treatment with 5uM 5-FU in MCF-7 
cells. Methods employed were as shown below. Data for 
Method B are original. Otherwise, obtained from Benz and 
coworkers (23) . 
Method A: [^H]-estradiol exchange on 100,OOOxg cytosol protein 
extract (Horwitz, et al) (74). 
Method B: [^H]-estradiol exchange on 30% NH4SO4. cut of 800xg 
whole cell lysate (Feldman, et al) (56). 
Method C: [%]-estradiol exchange on intact cultured cells 
(Shafie and Brooks) (141). 
Method D: Flow cytometric intensity of cellular bound fluorescein- 
conjugated estradiol (Raber et al) (127). 
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Group Trial fmol (3H) E2 Ratio fmol (%) E2 Ratio 
bound per 5-FU to bound per 5-FU to 
million cells Control mg protein Control 
5-FU 0.194 2.09 
1 1.67 2.65 
Control 0.116 0.79 
5-FU 0.609 6.80 
2 1.54 1.25 
Control 0.396 5.44 
5-FU 0.0634 1.42 
3 2.65 1.60 
Control 0.0239 0.885 
Mean 1.65 1.95 
SD 0.42 0.61 
Figure 21. When MCF-7 cells are incubated in 5uM 5-FU for 6 hours, 
specific binding of OF-OE^ to ER is increased compared to controls 
by 1.54 to 2.65 times (mean 1.65, SD 0.42) in the case of fmol 
(3H)E0 bound per million cells, or from 1.25 to 2.65 times (mean 
1.95, SD 0.61) in the case of fmol (3H)E bound per mg protein. 
Three separate experiments were conducted (Trials 1, 2 and 3). 
The results for each experiment are given under column 3, juxta¬ 
posing the value obtained for 5-FU with that for control cells. 
The ratio between the two is given in column 4. Columns 5 and 6 
show an alternate method of quantitating estrogen receptor specific 
binding. Neither method is ideal, since neither simultaneously 
controls for cell size and varying amounts of total cellular 
proteins; thus both are given here. 
Ideally, a dose-response relationship could have been 
established. However, these preliminary results do indicate a 
significant difference between control and 5-FU treated cells. 
' 
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